Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.
Elizabeth Lee, MD
Advertisement
Elizabeth Lee, MD, is a medical oncologist for the gynecology oncology program at Dana-Farber Cancer Institute in Boston, Massachusetts.
Articles by Elizabeth Lee, MD
Elizabeth Lee, MD, shares that rinatabart sesutecan’s mechanism of action may allow more patients with advanced endometrial cancer to receive effective treatment.
Advertisement
Latest Updated Articles
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer?January 14th 2026
- How Does Rina-S Work in Patients With Pretreated Endometrial Cancer?
February 5th 2026
Advertisement
Advertisement